Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

Purpose Ipilimumab increases antitumor T-cell responses by binding to cytotoxic T-lymphocyte antigen 4. We evaluated treatment with ipilimumab in asymptomatic or minimally symptomatic patients with chemotherapy-naive metastatic castration-resistant prostate cancer without visceral metastases. Patients and Methods In this multicenter, double-blind, phase III trial, patients were randomly assigned (2:1) to ipilimumab 10 mg/kg or placebo every 3 weeks for up to four doses. Ipilimumab 10 mg/kg or placebo maintenance therapy was administered to nonprogressing patients every 3 months. The primary end point was overall survival (OS). Results Four hundred patients were randomly assigned to ipilimumab and 202 to placebo; 399 were treated with ipilimumab and 199 with placebo. Median OS was 28.7 months (95% CI, 24.5 to 32.5 months) in the ipilimumab arm versus 29.7 months (95% CI, 26.1 to 34.2 months) in the placebo arm (hazard ratio, 1.11; 95.87% CI, 0.88 to 1.39; P = .3667). Median progression-free survival was 5.6 months in the ipilimumab arm versus 3.8 with placebo arm (hazard ratio, 0.67; 95.87% CI, 0.55 to 0.81). Exploratory analyses showed a higher prostate-specific antigen response rate with ipilimumab (23%) than with placebo (8%). Diarrhea (15%) was the only grade 3 to 4 treatment-related adverse event (AE) reported in ≥ 10% of ipilimumab-treated patients. Nine (2%) deaths occurred in the ipilimumab arm due to treatment-related AEs; no deaths occurred in the placebo arm. Immune-related grade 3 to 4 AEs occurred in 31% and 2% of patients, respectively. Conclusion Ipilimumab did not improve OS in patients with metastatic castration-resistant prostate cancer. The observed increases in progression-free survival and prostate-specific antigen response rates suggest antitumor activity in a patient subset.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Oct 31 [Epub]

Tomasz M Beer, Eugene D Kwon, Charles G Drake, Karim Fizazi, Christopher Logothetis, Gwenaelle Gravis, Vinod Ganju, Jonathan Polikoff, Fred Saad, Piotr Humanski, Josep M Piulats, Pablo Gonzalez Mella, Siobhan S Ng, Dirk Jaeger, Francis X Parnis, Fabio A Franke, Javier Puente, Roman Carvajal, Lisa Sengeløv, M Brent McHenry, Arvind Varma, Alfonsus J van den Eertwegh, Winald Gerritsen

Tomasz M. Beer, Oregon Health and Science University, Portland, OR; Eugene D. Kwon, Mayo Clinic, Rochester, MN; Charles G. Drake, Johns Hopkins University, Baltimore, MD; Karim Fizazi, University of Paris-Sud, Villejuif; Gwenaelle Gravis, Institut Paoli-Calmettes, Marseille, France; Christopher Logothetis, University of Texas MD Anderson Cancer Center, Houston, TX; Vinod Ganju, Monash University, Melbourne, Victoria; Siobhan S. Ng, St John of God Hospital, Subiaco, Western Australia; Francis X. Parnis, Adelaide Cancer Centre, Adelaide, South Australia, Australia; Jonathan Polikoff, Southern California Permanente Medical Group, San Marcos, CA; Fred Saad, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada; Piotr Humanski, Niepubliczny Zaklad Opieki Zdrowotnej Specjalista, Kutno, Poland; Josep M. Piulats, Institut Català d'Oncologia, Barcelona; Javier Puente, Hospital Clínico San Carlos, Madrid, Spain; Pablo Gonzalez Mella, Instituto Oncologico, Viña del Mar; Pablo Gonzalez Mella, Fundación Arturo Lopez Pérez, Santiago, Chile; Dirk Jaeger, University Hospital, Heidelberg, Germany; Fabio A. Franke, Hospital de Caridade de Ijuí, Ijuí, Brazil; Roman Carvajal, Hospital Regional Valentin Gomez Farias, Zapopan, Mexico; Lisa Sengeløv, Herlev Hospital, Herlev, Denmark; M. Brent McHenry, Bristol-Myers Squibb, Wallingford, CT; Arvind Varma, DOCS Inc, New York, NY; Alfonsus J. van den Eertwegh, VU University Medical Center, Amsterdam; and Winald Gerritsen, Radboud University, Nijmegen, the Netherlands.


Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.